Rakuten Medical eyes U.S. market for its novel idea to conquer cancer
Rakuten Medical CEO Minami Maeda in an interview in Yokohama in August | Kazuaki Nagata
Oct 9, 2026
Biotech startup Rakuten Medical is eyeing the U.S. market for its novel idea to conquer cancer — light illumination therapy.
The treatment, based on photoimmunotherapy — a combination of drug administration and illumination with red light — has long been in development as part of its Alluminox platform.
“We believe this could become a new platform for cancer treatment,” Minami Maeda, who became CEO of Rakuten Medical in July, said in a recent interview with The Japan Times.
In a time of both misinformation and too much information,
quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.